Navigation Links
Takeda to Acquire Nycomed
Date:5/18/2011

OSAKA, Japan, and ZURICH, May 19, 2011 /PRNewswire/ -- Takeda Pharmaceutical Company Limited ("Takeda", TSE: 4502) and Nycomed A/S ("Nycomed") jointly announced today that Takeda has reached an agreement with the shareholders of Nycomed in which Takeda will acquire the Zurich-headquartered company for 9.6 billion Euro on a cash-free, debt-free basis. The boards of directors of each company unanimously approved the transaction which is expected to be completed within 90 to 120 days, making it a wholly owned subsidiary of Takeda, subject to antitrust clearance. The purchase would exclude Nycomed's U.S. dermatology business.

The sellers are comprised of a consortium of private equity funds led by Nordic Capital Funds V and VI ("Nordic Capital"), including, DLJ Merchant Banking Partners (a Credit Suisse affiliate), Coller International Partners IV and V, and Avista Capital Partners.

This transformational transaction is a strategic fit with Takeda's sustainable growth strategy as it was outlined in its 2011–2013 Mid-Range Plan. Takeda has its strong presence in the Japanese and U.S. markets, while Nycomed has a significant business infrastructure in Europe and high-growth emerging markets that will enhance Takeda's regulatory development expertise and commercialization capability. The acquisition includes the roflumilast franchise (Daxas®; trade name in Europe), a first-in-class treatment for chronic obstructive pulmonary disease (COPD), which is expected to be a major source of revenue growth for Takeda. In addition, the acquisition will bring Takeda an immediate and stable increase in cash flow with Nycomed's more than 2.8 billion Euro in annual revenue, excluding the U.S. Dermatology business.

"Takeda is committed to transforming our organization through the acquisition of Nycomed. Nycomed enables Takeda to maximize the value of our portfolio and gives us an immediate strong presence in the high-growth emerging markets while doubling
'/>"/>

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Takeda Submits New Drug Application for Alogliptin (SYR-322) in the U.S.
2. Takeda Doses First Patient in a U.S. Phase 1 Study of Hematide(TM) to Treat Chemotherapy Induced Anemia
3. Takeda Submits a New Drug Application in the U.S. for Alogliptin (SYR-322) / ACTOS(R) (pioglitazone HCl) for the Treatment of Type 2 Diabetes
4. Takedas Investigational PPI TAK-390MR Demonstrated Higher Healing Rates Compared to Lansoprazole as the Severity of Erosive Esophagitis Grade Increased, a New Integrated Analysis Showed
5. Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer
6. Takeda Initiates Two Phase III Studies with Vedolizumab (MLN0002) in Patients with Inflammatory Bowel Disease
7. Takeda to Revise Timing of Alogliptin and Alogliptin/ACTOS MAA Filings in Europe
8. Takeda Receives FDA Complete Response Letter for Alogliptin, an Investigational Treatment for Type 2 Diabetes
9. Takeda Provides Update on the Investigational Fixed-Dose Combination of alogliptin and ACTOS(R) (pioglitazone HCl)
10. Takeda Initiates Cardiovascular Outcomes Trial for Alogliptin, An Investigational Treatment for Type 2 Diabetes
11. Takeda Receives FDA Complete Response Letter for the Investigational Fixed-Dose Combination of alogliptin and ACTOS(R) (pioglitazone HCl) for the Treatment of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/6/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/rvhg65/european_patient ) has ... Equipment Market by Product, by Type of Care, by ... report to their offering. The European ... a double-digit CAGR of 11.4% to reach $5,150.2 million ... geriatric population, increasing incidences of lifestyle diseases, and high ...
(Date:3/5/2015)... DETROIT , March 5, 2015   ... percent and met all seven optional leading indicators ... Benefit Management. "We are very proud ... said Rene Acker , Chief Operating Officer ... employees, dedication and commitment to transparency, flexibility and ...
(Date:3/5/2015)... March 5, 2015 Vermillion, Inc. (Nasdaq: ... focused on gynecologic disease, announced today it will ... the market open on Wednesday, March 25, 2015, ... at 8:30am Eastern. Conference Call & Webcast: ... Eastern/5:30am Pacific Domestic: , 800-753-9057International: , 913-981-5571Conference ID: ...
Breaking Medicine Technology:European Patient Handling Equipment (Wheelchair, Scooters, Bathroom Safety Supply, Mechanical, Ambulatory) Market 2015-2019 2European Patient Handling Equipment (Wheelchair, Scooters, Bathroom Safety Supply, Mechanical, Ambulatory) Market 2015-2019 3MeridianRx Earns Highest URAC Accreditation Status 2Vermillion to Report Fourth Quarter and Year-End 2014 Financial Results and Host an Investor Conference Call on March 25 2
(Date:3/6/2015)... York, New York (PRWEB) March 06, 2015 ... dancing’s dazzling days on the grand stage, to the silver ... Dancers sparkle throughout with precision toe-tapping numbers and their famous ... Karyn Tomczak deliver the rich history of tap dancing in ... forms to come out of the United States. , ...
(Date:3/6/2015)... 06, 2015 At Natural Products ... today the launch of its powerful, location-aware iOS ... and sustainable products at any retailer that carries ... at Expo West Booth 6054. , Makeena’s ... Kosher, non-GMO, organic, Paleo, and vegan, among many ...
(Date:3/6/2015)... First Choice Emergency Room opened its ... located at 13351 W. Bowles Avenue, Littleton, Colorado and is ... 24-7 to provide the highest quality emergency medical care to ... First Choice Emergency Room Littleton. , First Choice ... Denver Chamber of Commerce and a medical community open house ...
(Date:3/6/2015)... 06, 2015 Truly Nolen, the largest ... announce the grand opening of their first independently-owned and ... down to the Fort Mill – Rock Hill, SC ... 27th, 2015 at their new location. , ... of collective experience in the pest control industry. Locally ...
(Date:3/6/2015)... The Gluten-Free Certification Program (GFCP), ... pleased to announce that Dufflet Pastries, the ground-breaking ... their product line of gluten-free treats certified by ... as satisfying as any of their other desserts! ... contains hydrogenated fats or oils, artificial flavours, colours ...
Breaking Medicine News(10 mins):Health News:The Legacy Dancers, a Dazzling Dance Troupe of Former Rockettes, Kick to New Heights in “On Tap: From Broadway to the Silver Screen” 2Health News:Makeena Launches App that Makes Healthy and Sustainable Products More Affordable for Shoppers 2Health News:Makeena Launches App that Makes Healthy and Sustainable Products More Affordable for Shoppers 3Health News:First Choice Emergency Room Opens New Facility in Littleton, Colorado 2Health News:First Truly Nolen Franchise Opening in North Carolina 2Health News:Dufflet Pastries® Impressive Collection of Brownies, Cakes, Pies and Cakelets® Now Includes a Gluten-Free Line Certified By the GFCP. 2Health News:Dufflet Pastries® Impressive Collection of Brownies, Cakes, Pies and Cakelets® Now Includes a Gluten-Free Line Certified By the GFCP. 3Health News:Dufflet Pastries® Impressive Collection of Brownies, Cakes, Pies and Cakelets® Now Includes a Gluten-Free Line Certified By the GFCP. 4
... research team led by Queen,s University have developed a ... new drug will benefit sufferers who have the ,Celtic ... Ireland. The study, which was carried out by ... the Belfast Health and Social Care Trust and teams ...
... LOS ANGELES(June 20, 2011)Doctors warned of a potential public health ... and New York who developed serious skin reactions after smoking ... medication drug dealers are using to dilute, or "cut," up ... report, published online in the Journal of the American ...
... Although sex and infidelity are now only a keyboard ... no substitute for physical, face-to-face contact in our sexual ... Kholos Wysocki, from the University of Nebraska at Kearney, ... They investigated the behaviors of infidelity on the internet ...
... as lesbian, gay, or bisexual increases emotional well-being even ... benefits of revealing one,s sexual identity -- less anger, ... supportive settings, shows a study published June 20 in ... findings underscore the importance of creating workplaces and other ...
... SUNDAY, June 19 (HealthDay News) -- Dads don,t have to forego ... research that has linked red and processed meat consumption to ... M.D. Anderson Cancer Center say that small changes in what people ... toward lowering their risk of cancer. , , "The good news ...
... An international research team, co-led by scientists at ... potential susceptibility genes for development of progressive supranuclear ... symptoms similar to those of Parkinson,s disease ... being published online June 19 in Nature Genetics ...
Cached Medicine News:Health News:Scientists develop first ever drug to treat 'Celtic gene' in cystic fibrosis sufferers 2Health News:Adulterated cocaine causing serious skin reactions 2Health News:Let your fingers do the talking: Sexting and infidelity in cyberspace 2Health News:Is coming out always a good thing? 2Health News:Is coming out always a good thing? 3Health News:Dads Can Light Their Grills Without Fear 2Health News:Possible susceptibility genes found in neurodegenerative disorder 2Health News:Possible susceptibility genes found in neurodegenerative disorder 3
Arthrex has the most extensive offering of arthroscopic suture passing instruments,available anywhere in the world. We have speci? cally designed the function of our,instruments to work hand in hand ...
Arthrex has the most extensive offering of arthroscopic suture passing instruments,available anywhere in the world. We have speci? cally designed the function of our,instruments to work hand in hand ...
Arthrex has the most extensive offering of arthroscopic suture passing instruments,available anywhere in the world. We have speci? cally designed the function of our,instruments to work hand in hand ...
45 left angled suture passer....
Medicine Products: